search
Back to results

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

Primary Purpose

Colorectal Cancer

Status
Unknown status
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
UFT
USEL/Leucovorin
Krestin
Sponsored by
Hokkaido Gastrointestinal Cancer Study Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal Cancer,UFT,LV,Krestin,adjuvant therapy,phase III

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with primary colonic carcinoma or rectal carcinoma of histological stage III, who have undergone histological curability A or B surgeries Patients evaluated histologically as lymph node metastasis positive Patients aged between 20 and 80 years, inclusive, at the time of acquisition of informed consent Patients with performance status 0 to 2 Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy) Gastrointestinal function: Patients with no diarrhea (watery stool) Patients without severe impairment of renal, hepatic and bone marrow functions Patients with no serious concurrent complications (such as infection) Patients who have given written informed consent to participate in this study Exclusion Criteria: Patients graded as curability C Patients with stenosis not capable of oral intake Among disease stage IIIa cases, those that are si/n(-) and ai/n(-) Patients with fresh hemorrhage from the gastrointestinal tract Patients with retention of body fluid necessitating treatment Patients with infection, intestinal palsy or intestinal occlusion Patients with the lower end of the tumor involving the peritoneal reflection Patients with lower rectal cancer (Rb), involving the anal canal (P) or perianal skin (E) Patients with active multiple cancers; or even if the multiple cancers are metachronous, have a disease-free period of less than 5 years (but excluding cancer in situ and skin cancer) Patients who are pregnant or hope to become pregnant during the study period Patients with poorly controlled diabetes or are treated by continuous use of insulin Patients with a history of ischemic heart disease Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study Patients receiving continuous administration of steroids Patients who have experienced serious drug allergy in the past Others, patients judged by the investigator or subinvestigator to be inappropriate as subject

Sites / Locations

  • ・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

2

3

1

Arm Description

Outcomes

Primary Outcome Measures

3-years disease-free survival rate (DFS)

Secondary Outcome Measures

Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL

Full Information

First Posted
September 12, 2005
Last Updated
May 24, 2010
Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Collaborators
Hokkaido University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00209742
Brief Title
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
Official Title
Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2010
Overall Recruitment Status
Unknown status
Study Start Date
April 2005 (undefined)
Primary Completion Date
December 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Collaborators
Hokkaido University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized controlled study is conducted on patients with histological stage III colorectal cancer assigned to postoperative adjuvant therapy of uracil-tegafur plus leucovorin (UFT+LV), UFT+LV / UFT, or UFT+LV+PSK / UFT+PSK. The usefulness of the three regimens was evaluated by comparing the disease-free survival rate, overall survival rate, incidence and severity of adverse event, and quality of life.
Detailed Description
A multicenter randomized open-label controlled study is conducted on patients with histological stage III and curability A or B colorectal cancer [according to General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 6th edition (Japanese Classification of Colorectal Cancer, English edition), also according to pTNM classification to facilitate overseas publication] given postoperative oral therapy of tegafur-uracil plus leucovorin (UFT+LV) (5 courses), UFT+LV (5 courses) / UFT (1 year), or UFT+LV+PSK (5 courses) / UFT+PSK (1 year). The usefulness of the three regimens as postoperative adjuvant therapy was evaluated by comparing the disease-free survival rate (DFR), overall survival rate (OS), incidence and severity of adverse event, and quality of life (QOL).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
Colorectal Cancer,UFT,LV,Krestin,adjuvant therapy,phase III

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
340 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Experimental
Arm Title
1
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
UFT
Other Intervention Name(s)
tegafur-uracil
Intervention Description
P.O. everyday
Intervention Type
Drug
Intervention Name(s)
USEL/Leucovorin
Other Intervention Name(s)
Leucovorin
Intervention Description
P.O. everyday
Intervention Type
Drug
Intervention Name(s)
Krestin
Other Intervention Name(s)
PSK
Intervention Description
P.O. everyday
Primary Outcome Measure Information:
Title
3-years disease-free survival rate (DFS)
Time Frame
5-years
Secondary Outcome Measure Information:
Title
Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL
Time Frame
7-years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with primary colonic carcinoma or rectal carcinoma of histological stage III, who have undergone histological curability A or B surgeries Patients evaluated histologically as lymph node metastasis positive Patients aged between 20 and 80 years, inclusive, at the time of acquisition of informed consent Patients with performance status 0 to 2 Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy) Gastrointestinal function: Patients with no diarrhea (watery stool) Patients without severe impairment of renal, hepatic and bone marrow functions Patients with no serious concurrent complications (such as infection) Patients who have given written informed consent to participate in this study Exclusion Criteria: Patients graded as curability C Patients with stenosis not capable of oral intake Among disease stage IIIa cases, those that are si/n(-) and ai/n(-) Patients with fresh hemorrhage from the gastrointestinal tract Patients with retention of body fluid necessitating treatment Patients with infection, intestinal palsy or intestinal occlusion Patients with the lower end of the tumor involving the peritoneal reflection Patients with lower rectal cancer (Rb), involving the anal canal (P) or perianal skin (E) Patients with active multiple cancers; or even if the multiple cancers are metachronous, have a disease-free period of less than 5 years (but excluding cancer in situ and skin cancer) Patients who are pregnant or hope to become pregnant during the study period Patients with poorly controlled diabetes or are treated by continuous use of insulin Patients with a history of ischemic heart disease Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study Patients receiving continuous administration of steroids Patients who have experienced serious drug allergy in the past Others, patients judged by the investigator or subinvestigator to be inappropriate as subject
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Masahiro Asaka, MD, PhD
Organizational Affiliation
Hokkaido Gastrointestinal Cancer Study Group
Official's Role
Study Chair
Facility Information:
Facility Name
・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine)
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
060-8638
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

We'll reach out to this number within 24 hrs